Eagle Pharmaceuticals to Discuss Fourth Quarter and Full Year 2019 Financial Results on March 2, 2020
February 19, 2020WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2019 fourth quarter and full year financial results on Monday, March 2, 2020, before the market opens.
Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results as follows:
|
Date |
Monday, March 2, 2020 |
|
|
Time |
8:30 a.m. EST |
|
|
Toll free (U.S.) |
877-876-9173 |
|
|
International |
785-424-1667 |
|
|
Webcast (live and replay) |
www.eagleus.com, under the “Investor Relations” section |
A replay of the conference call will be available for one week after the call’s completion by dialing 800-839-3020 (US) or 402-220-7234 (International) and entering conference call ID EGRXQ419. The webcast will be archived for 30 days at the aforementioned URL.
About Eagle Pharmaceuticals, Inc.
Eagle is a pharmaceutical company focused on developing and commercializing innovative and differentiated injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Additional information is available on the Company’s website at www.eagleus.com.
Contacts
Investor Relations for Eagle Pharmaceuticals, Inc:
Lisa M. Wilson
T: 212-452-2793
E: [email protected]
Public Relations for Eagle Pharmaceuticals, Inc.:
Rose Ramseth
WE Communications
T: 212-551-4841
M: 206-898-7551
E: [email protected]